BCL2L1 and glioblastoma: A marked Bcl-xL overexpression is associated with the clinical stage of GBM (CGGA-dataset) and worse survival for both primary and recurrent brain tumors (CGGA-dataset, TCGA-dataset) (Fig. 1C–F).